Dissociation between phosphodiesterase inhibition and antiproliferative effects of phosphodiesterase inhibitors on the Dami cell line

Biochemical Pharmacology

Volumn 53, Issue 8, 1997, Pages 1141-1147

  Zurbonsen, Katja ^a   Michel, Alain ^b   Vittet, Daniel ^a   Bonnet, Pierre Antoine ^b   Chevillard, Claude ^a  

^a INSERM   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

cAMP; Dami cell line; megakaryoblast; PDE inhibitors; PDE isoenzymes; proliferation

Indexed keywords

1 (3 CHLOROANILINO) 4 PHENYLPHTHALAZINE; 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; 8 MEOMIX; CYCLIC AMP; ISOENZYME; MILRINONE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; ROLIPRAM; TREQUINSIN; UNCLASSIFIED DRUG; ZAPRINAST;

ARTICLE; CELL LINE; CELL PROLIFERATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; MEGAKARYOBLAST; PRIORITY JOURNAL;

4-(3-BUTOXY-4-METHOXYBENZYL)-2-IMIDAZOLIDINONE; ALPROSTADIL; CELL DIVISION; CYCLIC AMP; HUMANS; ISOENZYMES; ISOQUINOLINES; L-LACTATE DEHYDROGENASE; LEUKEMIA, MEGAKARYOCYTIC, ACUTE; MILRINONE; PHOSPHODIESTERASE INHIBITORS; PHTHALAZINES; PYRIDONES; PYRROLIDINONES; ROLIPRAM; TETRAHYDROISOQUINOLINES; TUMOR CELLS, CULTURED;

EID: 0030950748     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00822-2     Document Type: Article

References (43)

1. Dumont JE, Jauniaux JC and Roger PP, The cyclic AMP-mediated stimulation of cell proliferation. Trends Biochem Sci 14: 67-71, 1989.
2. Boynton AL and Whitfield JF, The role of cyclic AMP in cell proliferation: a critical assessment of the evidence. Adv Cyclic Nucleotide Res 15: 193-294, 1983.
3. Cho-Chung YS, Role of cyclic AMP receptor proteins in growth, differentiation and suppression of malignancy: new approaches to therapy. Cancer Res 50: 7093-7100, 1990.
4. Cho-Chung YS, Clair T, Tortora G and Yokozaki H, Role of site-selective cAMP analogs in the control and reversal of malignancy. Pharmacol Ther 50: 1-33, 1991.
5. Vittet D, Duperray C and Chevillard C, Cyclic-AMP inhibits cell growth and negatively interacts with platelet membrane glycoprotein expression on the Dami human megakaryoblastic cell line. J Cell Physiol 163: 645-655, 1995.
6. Leitman DC, Fiscus RP and Murad F, Forskolin, phosphodiesterase inhibitors, and cyclic AMP analogs inhibit proliferation of cultured bovine aortic endothelial cells. J Cell Physiol 127: 237-243, 1986.
7. Lando M, Abemayor E, Verity MA and Sidell N, Modulation of intracellular cyclic adenosine monophosphate levels and the differentiation response of human neuroblastoma cells. Cancer Res 50: 722-727, 1990.
8. Prasad KN and Sheppard JR, Inhibitors of cyclic nucleotide phosphodiesterase induce morphological differentiation of mouse neuroblastoma cell culture. Exp Cell Res 73: 436-440, 1972.
9. Janik P, Assaf A and Bertram JS, Inhibition of growth of primary and metastatic Lewis lung carcinoma cells by the phosphodiesterase inhibitor isobutylmethylxanthine. Cancer Res 40: 1950-1954, 1980.
10. Fontana JA, Miksis G, Miranda DM and Durham JP, Inhibition of human mammary carcinoma cell proliferation by retinoids and intracellular cAMP-elevating compounds. J Natl Cancer Inst 78: 1107-1112, 1987.
11. Biddle W, Montagna RA, Leong SS, Horoszewicz J, Gastpar H and Ambrus JL, Antineoplastic effect of the pyrimido-pyrimidine derivative: RA 233. Pathol Biol 32: 9-13, 1984.
12. Lichtner RB, Goka TJ, Butcher RW and Nicolson GL, Direct effects of the pyrimido-pyrimidine derivative RA 233 (Rapenton) on rat 13762NF mammary tumor cell clones in vitro. Cancer Res 47: 1870-1877, 1987.
13. Lichtner RB and Nicolson GL, The pyrimido-pyrimidine derivatives RA 233 and RX-RA 85 affect growth and cytosketal organization of rat mammary adenocarcinoma cells. Eur J Cancer Clin Oncol 23: 1269-1275, 1987.
14. Levallois C, Bonnafous JC, Françoise MA, Sablayrolles C, Chapat JP and Mani JC, Theophylline-like properties of xanthine analogs. Biochem Pharmacol 33: 2253-2257, 1984.
15. Beavo JA, Conti M and Heaslip RJ, Multiple cyclic nucleotide phosphodiesterases. Mol Pharmacol 46: 399-405, 1994.
16. Nicholson CD, Challiss RAJ and Shahid M, Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci 12: 19-27, 1991.
17. Beavo JA and Reifsnyder DH, Primary sequence of cyclic nucleotide phosphodiesterase isoenzymes and the design of selective inhibitors. Trends Pharmocol Sci 11: 150-155, 1990.
18. Marcoz P, Prigent AF, Lagarde M and Nemoz G, Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents. Mol Pharmacol 44: 1027-1035, 1993.
19. Banner KH and Page CP, Effect of type III and IV isoenzyme selective phosphodiesterase (PDE) inhibitors on proliferation of human peripheral blood mononuclear cells. Br J Pharmacol 113: 89P, 1994.
20. Takahashi S, Oida K, Fujiwara R, Maeda H, Hayashi S, Takai H, Tamai T, Nakai T and Miyabo S, Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovosc Pharmacol 20: 900-906, 1992.
21. Souness JE, Hassall GA and Parrott DP, Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. Biochem Pharmacol 44: 857-866, 1992.
22. Pan X, Arauz E, Krzanowski JJ, Fitzpatrick DF and Poison JB, Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Biochem Pharmacol 48: 827-835, 1994.
23. Dress M, Zimmermann R and Eisenbrand G, 3′,5′-cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition. Cancer Res 53: 3058-3061, 1993.
24. Greenberg SM, Rosenthal DS, Greeley TA, Tantravahi R and Handin RI, Characterization of a new megakaryocytic cell line: The Dami cell. Blood 72: 1968-1977, 1988.
25. Decker T and Lohmann-Matthes ML, A quick and simple method for the quantification of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 115: 61-69, 1988.
26. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ, Protein measurement with the Folin phenol reagent. J Biol Chem 193: 365-375, 1951.
27. Thompson WJ, Terasaki W, Epstein PM and Strada SJ, Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme. Adv Cycl Nucl Res 10: 69-92, 1979.
28. Cook SJ, Archer K, Martin A, Buchheit KH, Fozard JR, Müller T, Miller AJ, Elliot KRF, Foster RW and Small RC, Further analysis of the mechanisms underlying the tracheal relaxant action of SCA40. Br J Pharmocol 114: 143-151, 1995.
29. Tallarida RJ and Murray RB, Manual of Pharmacologic Calculation with Computer Programs. Springer Verlag, New York, 1981.
30. Viswanadhan VN, Ghose AK, Revankar GR and Robins RK, Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occuring nucleoside antibiotics. J Chem Infr Comput Sci 29: 163-172, 1989.
31. Ruppert D and Weithmann KU, HL 725, an extremely potent inhibitor of platelet phosphodiesterase induced platelet aggregation in vitro. Life Sci 31, 2037-2043, 1982.
32. Sheppard H, Wiggan G and Tsien WH, Structure activity relationships for inhibitors of phosphodiesterase from erythrocytes and other tissues. Adv Cyclic Nucleotide Res 1: 103-112, 1972.
33. Hagiwara M, Endo T, Kanayama T and Hidaka H, Effect of 1-(3-chloroanilino)-4-phenylphthalazine (MY-5445), a specific inhibitor of cyclic GMP phosphodiesterase, on human platelet aggregation. J Pharmacol Exp Ther 228: 467-471, 1984.
34. Harrison SA, Reifsnyder DA, Gallis B, Cadd GG and Beavo JA, Isolation and characterisation of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs. Mol Pharmacol 29: 506-514, 1986.
35. Schneider HH, Schmiechen R, Brezinski M and Seidler J, Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol 127: 105-115, 1986.
36. Gillespie PG and Beavo JA, Inhibition and stimulation of photoreceptor phosphodiesterases by dipyridamole and M&B 22,948. Mol Pharmacol 36: 773-781, 1989.
37. Beavo JA, Cyclic nucleotide phosphodiesterase: Functional implications of multiple isoforms. Physiol Rev 75: 725-748, 1995.
38. Tomes C, Rossi S and Moreno S, Isobutylmethylxanthine and other classical cyclic nucleotide phosphodiesterase inhibitors affect cAMP-dependent protein kinase activity. Cell Signalling 5: 615-621, 1993.
39. Parsons WJ, Ramkumar V and Stiles GL, Isobutylmethylxanthine stimulates adenylate cyclase by blocking the inhibitory regulatory protein, Gi. Mol Pharmacol 34: 37-41, 1988.
40. Manganiello VC, Murata T, Taira M, Belfrage P and Degerman E, Perspectives in biochemistry and biophysics -diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Arch Biochem Biophys 322: 1-13, 1995.
41. 2+ rise and phosphoinositide hydrolysis. Biochem J 234: 555-562, 1986.
42. Pyne NJ and Burns F, Lung phosphodiesterase isoenzymes. Agents Actions Suppl 43: 35-49, 1993.
43. Burns F and Pyne NJ, Interaction of the catalytic subunit of protein kinase A with the lung type V cyclic GMP phosphodiesterase: modulation of non-catalytic binding sites. Biochem Biophys Res Commun 189: 1389-1396, 1992.